CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed
Drug / intervention
Pyrimethamine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00000643
NCT00000643Phase 2Completed
CompareCT.gov

Primary Prophylaxis of Cerebral Toxoplasmosis in HIV-Infected Patients

National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 2, 2021

In Brief

A Phase 2 clinical trial evaluating Pyrimethamine and Leucovorin calcium for Toxoplasmosis, Cerebral and HIV Infections. Completed, across 24 sites.

Detailed Summary

To evaluate the effectiveness of pyrimethamine (given with leucovorin calcium versus placebo (an inactive substance) for the primary prophylaxis (prevention) of cerebral toxoplasmosis in HIV-infected patients. Cerebral toxoplasmosis is one of the most frequently encountered opportunistic infections in the course of AIDS. The mortality (death) rate is estimated to be greater than 50 percent. Pyrimethamine is a drug that appears promising for the primary prevention of cerebral toxoplasmosis in HIV-infected patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsToxoplasmosis, Cerebral, HIV Infections
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
1994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 31, 2001
Study CompletionMay 1, 1994
TodayJul 2, 2026
Posted 24.8 years ago

Interventions

Pyrimethaminedrug

Leucovorin calciumdrug